What question did this study set out to answer?

To evaluate the clinical efficacy and safety of a highly purified porcine factor VIII concentrate (Hyate:C) in managing severe bleeding episodes in patients with high-responding factor VIII inhibitors.

June 1, 1989Archives of Internal Medicine

The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIII

View Full Paper

Ask AI

Bookmark

Authors

DBDoreen B. BrettlerUniversity of Massachusetts Chan Medical School

Discussion

Member takes

Implication

Multicenter study reveals good clinical efficacy of porcine factor VIII in hemophilia patients with high-titer inhibitors, suggesting its early use in severe hemorrhages.

Key Points

To evaluate the clinical efficacy and safety of a highly purified porcine factor VIII concentrate (Hyate:C) in managing severe bleeding episodes in patients with high-responding factor VIII inhibitors.
Evaluation of 437 infusions administered across 45 bleeding episodes in 38 patients with high-responding factor VIII inhibitors.
Patients were treated across 25 hemophilia centers in the United States, primarily for life- or limb-threatening hemorrhages refractory to other therapies.
Good to excellent clinical responses were achieved in 32 of 45 bleeding episodes (71.1%).
Adverse reactions occurred in 17 treatment episodes and were largely managed with antihistamines, hydrocortisone, or both, although anamnestic antibody responses occurred in some instances.
Pretreatment human and porcine inhibitor levels, cross-reactivity percentages, and measurable post-infusion factor VIII levels did not clearly predict clinical response.

Cite This Study

Doreen B. Brettler (1989) studied this question.

synapsesocial.com/papers/6a6fe24d87f9210571275ed2 https://doi.org/10.1001/archinte.1989.00390060103022

View Full Paper

Ask AI

Bookmark

Implication

Multicenter study reveals good clinical efficacy of porcine factor VIII in hemophilia patients with high-titer inhibitors, suggesting its early use in severe hemorrhages.

The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIII

Discussion

Member takes

Implication

Key Points

Cite This Study

The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIII

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider